Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-02-15, Stock:NVS, The news for the past five days is as follows:
2018-02-08: NEWS1: Top Research Reports for Novartis, BP & Biogen.NEWS2: Top Research Reports for Novartis, BP & Biogen.NEWS3: How Pfizer’s Business Segments Performed in 4Q17.NEWS4: Pfizer Reports Revenue Growth in 4Q17.NEWS5: Top Research Reports for Novartis, BP & Biogen.NEWS6: Amgen’s Repatha and Blincyto: How They Did in 3Q17.NEWS7: Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis.NEWS8: Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis.NEWS9: Novartis&apos; Cosentyx Label Expanded to Include Scalp Psoriasis.NEWS10: Imbruvica Leads in the Chronic Lymphocytic Leukemia Space.NEWS11: Patient Advocate Says Novartis' $475,000 Breakthrough Should Cost Just $160,000.NEWS12: The Swiss Stock Market Dropped To Its Lowest Level Since April.NEWS13: The Swiss Stock Market Dropped To Its Lowest Level Since April.NEWS14: Glaxo's Key Drug Gains Time as FDA Denies Novartis Generic.NEWS15: Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed.NEWS16: Novartis Gets FDA Approval For Cosentyx Label Update - Quick Facts.NEWS17: Novartis Gets FDA Approval For Cosentyx Label Update - Quick Facts.
2018-02-09: NEWS1: [$$] Novartis Faces Investigation For Alleged Bribery In Greece.NEWS2: What’s Expected of Novartis’s Core Operating Income in 2018?.NEWS3: Why Novartis Is Expected to Report Modest Revenue Growth in 2018.NEWS4: Novartis and Peers in February 2018: Analyst Recommendations.NEWS5: The Zacks Analyst Blog Highlights: Novartis, BP and Biogen.NEWS6: The Zacks Analyst Blog Highlights: Novartis, BP and Biogen.NEWS7: Analyst: Regeneron Is Undervalued By The Street.NEWS8: A Look at Amgen’s Nplate, Vectibix, and Neupogen in 4Q17.NEWS9: Why Sanofi Has Received a Negative Outlook from Fitch Ratings.NEWS10: Will Teva Pharmaceutical's Pain Be Mylan's Gain?.NEWS11: Will Teva Pharmaceutical's Pain Be Mylan's Gain?.NEWS12: The Zacks Analyst Blog Highlights: Novartis, BP and Biogen.NEWS13: How the Ablynx Acquisition Strengthens Sanofi’s R&D Strategy.NEWS14: How Amgen’s Xgeva and Prolia Performed in 4Q17.NEWS15: Ablynx Acquisition Strengthens SNY’s Rare Blood Disorder Platform.NEWS16: The Swiss Stock Market Ends Another Turbulent Session In The Red.NEWS17: The Swiss Stock Market Ends Another Turbulent Session In The Red.
2018-02-12: NEWS1: Bristol-Myers Squibb’s Oncology Portfolio in 4Q17.NEWS2: Regeneron Could Benefit From &apos;Lackluster&apos; Data Presented By These Rivals.NEWS3: Pfizer’s Bosulif Had a Strong Performance in 4Q17 and 2017.NEWS4: Pfizer’s Inlyta: Analyzing Revenue Trends.NEWS5: Greek PM wants politicians investigated in alleged Novartis bribery case.NEWS6: Greek PM wants politicians investigated in alleged Novartis bribery case.NEWS7: Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings?.NEWS8: Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings?.NEWS9: How’s Pfizer’s Oncology Business Positioned after 2017?.NEWS10: Cardinal Health a Top Ranked SAFE Dividend Stock With 2.8% Yield (CAH).NEWS11: Cardinal Health a Top Ranked SAFE Dividend Stock With 2.8% Yield (CAH).NEWS12: Why Novartis’s Entresto Could Witness a Robust Demand Trend in 2018.NEWS13: What Could Drive Amgen’s Long-Term Growth?.NEWS14: How Much Profit Should Novartis Earn By Curing A Childhood Leukemia?.NEWS15: What’s Expected of Novartis’s Net Profit Margin in 2018?.NEWS16: The Swiss Stock Market Starts The Week With A Gain.NEWS17: The Swiss Stock Market Starts The Week With A Gain.NEWS18: European Markets Recover Some Lost Ground.NEWS19: European Markets Recover Some Lost Ground.NEWS20: GlaxoSmithKline plc -- Moody's: M&A greatest downside risk to European pharma companies' credit quality in 2018.NEWS21: European Shares Rebound From Six-month Lows.NEWS22: European Shares Rebound From Six-month Lows.NEWS23: Better Buy: Pfizer Inc. (PFE) vs. Eli Lilly (LLY).NEWS24: Better Buy: Pfizer Inc. (PFE) vs. Eli Lilly (LLY).
2018-02-13: NEWS1: Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug.NEWS2: Postponed Common Share Consolidation and Name Change.NEWS3: IIROC Trading Halt - NVS.NEWS4: Analyzing Pfizer’s Ibrance and Xalkori after 2Q17.NEWS5: Intercept Starts OCA Trial for NASH Patients With Cirrhosis.NEWS6: Intercept Starts OCA Trial for NASH Patients With Cirrhosis.NEWS7: Novartis gains U.S. approval for delayed MS drug.NEWS8: Teva shares drop 3% after rival generic product approved and launched.NEWS9: Pfizer’s Sutent Generated Higher Revenues in 4Q17.NEWS10: Novartis gains U.S. approval for delayed MS drug.NEWS11: The Swiss Stock Market Pulled Back On Inflation Concerns.NEWS12: The Swiss Stock Market Pulled Back On Inflation Concerns.NEWS13: Sandoz Announces FDA Approval Of Glatopa - Quick Facts.NEWS14: Sandoz Announces FDA Approval Of Glatopa - Quick Facts.
2018-02-14: NEWS1: 3 Reasons to Be Bullish on Pfizer Inc. Stock.NEWS2: 3 Reasons to Be Bullish on Pfizer Inc. Stock.NEWS3: Teva Stock Falls as Novartis Brings Another Copaxone Generic.NEWS4: Teva Stock Falls as Novartis Brings Another Copaxone Generic.NEWS5: Lilly's Taltz Positive in Phase III Label Expansion Study.NEWS6: Lilly's Taltz Positive in Phase III Label Expansion Study.NEWS7: 3 Reasons to Be Bullish on Pfizer Inc. Stock.NEWS8: Teva Stock Falls as Novartis Brings Another Copaxone Generic.NEWS9: IIROC Trade Resumption - NVS.NEWS10: IIROC Trade Resumption - NVS.NEWS11: The Swiss Stock Market Regained Some Lost Ground.NEWS12: The Swiss Stock Market Regained Some Lost Ground.NEWS13: Generic Drugmakers to Dump as Teva's Woes Continue in 2018.NEWS14: Generic Drugmakers to Dump as Teva's Woes Continue in 2018.

Answer: Rise